Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCTIC: Durvalumab ± Tremelimumab vs Standard of Care in Previously Treated Advanced NSCLC
jRCT2080222776Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2015
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of durvalumab and tremelimumab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by AstraZeneca. Started Mar 2015; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080222776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222776.